Skip to main content

Advertisement

SpringerLink
Log in

Estrogen-Mediated Protection in Myocardial Ischemia-Reperfusion Injury

  • Review
  • Published:
Cardiovascular Toxicology Aims and scope Submit manuscript

Abstract

Before menopause, a woman has a relatively low risk for developing cardiovascular disease. After menopause, however, the risk increases nearly twofold and cardiovascular disease remains the number one cause of death among women. Observational trials and studies in animal models of cardiovascular disease suggested that females have reduced injury after myocardial ischemia and reperfusion injury. However, two large clinical trials, the women’s health initiative (WHI) and the heart estrogen and progestin replacement study (HERS), found an increase in cardiovascular incidences in women taking hormone replacement therapy. The discrepancy between these data highlights the need for further research on the mechanism of estrogen in the cardiovascular system. Animal studies have demonstrated protective effects by endogenous estrogen (gender differences) and also by the administration of exogenous estrogen. In vivo studies suggest a possible anti-inflammatory mechanism of estrogen. Exogenous estrogen has been shown to have anti-oxidant activities. Pre-treatment with estrogen prior to myocardial ischemia and reperfusion causes a decrease in neutrophil infiltration into the irreversibly injured myocardium, decrease in C-reactive protein expression, and deposition of the membrane attack complex. This review will summarize the protection afforded by estrogen as well as discuss several possible mechanisms of protection for exogenous estrogen administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Acconcia, F., Ascenzi, P., Bocedi, A., Spisni, E., Tomasi, V., Trentalance, A., et al. (2005). Palmitoylation-dependent estrogen receptor alpha membrane localization: Regulation by 17beta-estradiol. Molecular Biology of the Cell, 16, 231–237. doi:10.1091/mbc.E04-07-0547.

    PubMed  CAS  Google Scholar 

  2. Acconcia, F., Ascenzi, P., Fabozzi, G., Visca, P., & Marino, M. (2004). S-palmitoylation modulates human estrogen receptor-alpha functions. Biochemical and Biophysical Research Communications, 316, 878–883. doi:10.1016/j.bbrc.2004.02.129.

    PubMed  CAS  Google Scholar 

  3. Adams, M. R., Kaplan, J. R., Manuck, S. B., Koritnik, D. R., Parks, J. S., Wolfe, M. S., et al. (1990). Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis (Dallas, Tex.), 10, 1051–1057.

    CAS  Google Scholar 

  4. Adams, M. R., Register, T. C., Golden, D. L., Wagner, J. D., & Williams, J. K. (1997). Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 217–221.

    PubMed  CAS  Google Scholar 

  5. Alcindor, D., Krolikowski, J. G., Pagel, P. S., Warltier, D. C., & Kersten, J. R. (2004). Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. Anesthesiology, 100, 547–554. doi:10.1097/00000542-200403000-00013.

    PubMed  CAS  Google Scholar 

  6. Bae, S., & Zhang, L. (2005). Gender differences in cardioprotection against ischemia/reperfusion injury in adult rat hearts: Focus on Akt and protein kinase C signaling. The Journal of Pharmacology and Experimental Therapeutics, 315, 1125–1135. doi:10.1124/jpet.105.090803.

    PubMed  CAS  Google Scholar 

  7. Barp, J., Araujo, A. S., Fernandes, T. R., Rigatto, K. V., Llesuy, S., Bello-Klein, A., et al. (2002). Myocardial antioxidant and oxidative stress changes due to sex hormones. Brazilian Journal of Medical and Biological Research, 35, 1075–1081. doi:10.1590/S0100-879X2002000900008.

    PubMed  CAS  Google Scholar 

  8. Barrett-Connor, E., & Grady, D. (1998). Hormone replacement therapy, heart disease, and other considerations. Annual Review of Public Health, 19, 55–72. doi:10.1146/annurev.publhealth.19.1.55.

    PubMed  CAS  Google Scholar 

  9. Barrett-Connor, E., Grady, D., Sashegyi, A., Anderson, P. W., Cox, D. A., Hoszowski, K., et al. (2002). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. Journal of the American Medical Association, 287, 847–857. doi:10.1001/jama.287.7.847.

    PubMed  CAS  Google Scholar 

  10. Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., et al. (2006). Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. The New England Journal of Medicine, 355, 125–137. doi:10.1056/NEJMoa062462.

    PubMed  CAS  Google Scholar 

  11. Beck, J. I., Boothroyd, C., Proctor, M., Farquhar, C., & Hughes, E. (2005). Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation. Cochrane Database of Systematic Reviews (Online: Update Software), CD002249.

  12. Bolli, R., Shinmura, K., Tang, X. L., Kodani, E., Xuan, Y. T., Guo, Y., et al. (2002). Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovascular Research, 55, 506–519. doi:10.1016/S0008-6363(02)00414-5.

    PubMed  CAS  Google Scholar 

  13. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine, 343, 1520–1528, 1522 p following 1528.

    Google Scholar 

  14. Booth, E. A., Marchesi, M., Kilbourne, E. J., & Lucchesi, B. R. (2003). 17Beta-estradiol as a receptor-mediated cardioprotective agent. The Journal of Pharmacology and Experimental Therapeutics, 307, 395–401. doi:10.1124/jpet.103.054205.

    PubMed  CAS  Google Scholar 

  15. Booth, E. A., Marchesi, M., Knittel, A. K., Kilbourne, E. J., & Lucchesi, B. R. (2007). The pathway-selective estrogen receptor ligand WAY-169916 reduces infarct size after myocardial ischemia and reperfusion by an estrogen receptor dependent mechanism. Journal of Cardiovascular Pharmacology, 49, 401–407. doi:10.1097/FJC.0b013e3180544527.

    PubMed  CAS  Google Scholar 

  16. Booth, E. A., Obeid, N. R., & Lucchesi, B. R. (2005). Activation of estrogen receptor-alpha protects the in vivo rabbit heart from ischemia-reperfusion injury. American Journal of Physiology. Heart and Circulatory Physiology, 289(5), H2039–H2047. doi:10.1152/ajpheart.00479.2005.

    PubMed  CAS  Google Scholar 

  17. Bradbury, B. D., Lash, T. L., Kaye, J. A., & Jick, S. S. (2005). Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer, 103, 1114–1121. doi:10.1002/cncr.20900.

    PubMed  CAS  Google Scholar 

  18. Braquet, P., Touqui, L., Shen, T. Y., & Vargaftig, B. B. (1987). Perspectives in platelet-activating factor research. Pharmacological Reviews, 39, 97–145.

    PubMed  CAS  Google Scholar 

  19. Chadwick, C. C., Chippari, S., Matelan, E., Borges-Marcucci, L., Eckert, A. M., Keith, J. C., Jr., et al. (2005). Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proceedings of the National Academy of Sciences of the United States of America, 102, 2543–2548. doi:10.1073/pnas.0405841102.

    PubMed  CAS  Google Scholar 

  20. Chambliss, K. L., Yuhanna, I. S., Mineo, C., Liu, P., German, Z., Sherman, T. S., et al. (2000). Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circulation Research, 87, E44–E52.

    PubMed  CAS  Google Scholar 

  21. Clarkson, T. B., Anthony, M. S., & Wagner, J. D. (2001). A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. The Journal of Clinical Endocrinology and Metabolism, 86, 5396–5404. doi:10.1210/jc.86.11.5396.

    PubMed  CAS  Google Scholar 

  22. Coker, S. J., & Parratt, J. R. (1985). AH23848, a thromboxane antagonist, suppresses ischaemia and reperfusion-induced arrhythmias in anaesthetized greyhounds. British Journal of Pharmacology, 86, 259–264.

    PubMed  CAS  Google Scholar 

  23. Collins, P., & Webb, C. (1999). Estrogen hits the surface. Nature Medicine, 5, 1130–1131. doi:10.1038/13453.

    PubMed  CAS  Google Scholar 

  24. Couse, J. F., & Korach, K. S. (1999). Estrogen receptor null mice: What have we learned and where will they lead us? Endocrine Reviews, 20, 358–417. doi:10.1210/er.20.3.358.

    PubMed  CAS  Google Scholar 

  25. Cross, H. R., Kranias, E. G., Murphy, E., & Steenbergen, C. (2003). Ablation of PLB exacerbates ischemic injury to a lesser extent in female than male mice: Protective role of NO. American Journal of Physiology. Heart and Circulatory Physiology, 284, H683–H690.

    PubMed  CAS  Google Scholar 

  26. Cross, H. R., Lu, L., Steenbergen, C., Philipson, K. D., & Murphy, E. (1998). Overexpression of the cardiac Na+/Ca2+ exchanger increases susceptibility to ischemia/reperfusion injury in male, but not female, transgenic mice. Circulation Research, 83, 1215–1223.

    PubMed  CAS  Google Scholar 

  27. Cross, H. R., Murphy, E., Koch, W. J., & Steenbergen, C. (2002). Male and female mice overexpressing the beta(2)-adrenergic receptor exhibit differences in ischemia/reperfusion injury: Role of nitric oxide. Cardiovascular Research, 53, 662–671. doi:10.1016/S0008-6363(01)00528-4.

    PubMed  CAS  Google Scholar 

  28. Cross, H. R., Steenbergen, C., Lefkowitz, R. J., Koch, W. J., & Murphy, E. (1999). Overexpression of the cardiac beta(2)-adrenergic receptor and expression of a beta-adrenergic receptor kinase-1 (betaARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. Circulation Research, 85, 1077–1084.

    PubMed  CAS  Google Scholar 

  29. Das, B., & Sarkar, C. (2006). Similarities between ischemic preconditioning and 17beta-estradiol mediated cardiomyocyte KATP channel activation leading to cardioprotective and antiarrhythmic effects during ischemia/reperfusion in the intact rabbit heart. Journal of Cardiovascular Pharmacology, 47, 277–286. doi:10.1097/01.fjc.0000202563.54043.d6.

    PubMed  CAS  Google Scholar 

  30. Decensi, A., Maisonneuve, P., Rotmensz, N., Bettega, D., Costa, A., Sacchini, V., et al. (2005). Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation, 111, 650–656. doi:10.1161/01.CIR.0000154545.84124.AC.

    PubMed  CAS  Google Scholar 

  31. Decensi, A., Omodei, U., Robertson, C., Bonanni, B., Guerrieri-Gonzaga, A., Ramazzotto, F., et al. (2002). Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation, 106, 1224–1228. doi:10.1161/01.CIR.0000028463.74880.EA.

    PubMed  CAS  Google Scholar 

  32. Delyani, J. A., Murohara, T., Nossuli, T. O., & Lefer, A. M. (1996). Protection from myocardial reperfusion injury by acute administration of 17 beta-estradiol. Journal of Molecular and Cellular Cardiology, 28, 1001–1008. doi:10.1006/jmcc.1996.0093.

    PubMed  CAS  Google Scholar 

  33. Deshpande, R., Khalili, H., Pergolizzi, R. G., Michael, S. D., & Chang, M. D. (1997). Estradiol down-regulates LPS-induced cytokine production and NFκB activation in murine macrophages. American Journal of Reproductive Immunology (New York, N.Y.), 38, 46–54.

    CAS  Google Scholar 

  34. DeWitt, D. L. (1991). Prostaglandin endoperoxide synthase: Regulation of enzyme expression. Biochimica et Biophysica Acta, 1083, 121–134.

    PubMed  CAS  Google Scholar 

  35. Dubey, R. K., Jackson, E. K., Gillespie, D. G., Zacharia, L. C., Imthurn, B., & Keller, P. J. (2000). Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 964–972.

    PubMed  CAS  Google Scholar 

  36. Egan, K. M., Lawson, J. A., Fries, S., Koller, B., Rader, D. J., Smyth, E. M., et al. (2005). Cyclooxygenase-2-derived prostacyclin confers atheroprotection on female mice. Obstetrical & Gynecological Survey, 60, 309–310. doi:10.1097/01.ogx.0000160574.33752.4f.

    Google Scholar 

  37. Ensrud, K., Genazzani, A. R., Geiger, M. J., McNabb, M., Dowsett, S. A., Cox, D. A., et al. (2006). Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. The American Journal of Cardiology, 97, 520–527. doi:10.1016/j.amjcard.2005.09.083.

    PubMed  CAS  Google Scholar 

  38. Evans, M. J., Eckert, A., Lai, K., Adelman, S. J., & Harnish, D. C. (2001). Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo. Circulation Research, 89, 823–830. doi:10.1161/hh2101.098543.

    PubMed  CAS  Google Scholar 

  39. Fischer, G. M., & Swain, M. L. (1985). Effects of estradiol and progesterone on the increased synthesis of collagen in atherosclerotic rabbit aortas. Atherosclerosis, 54, 177–185. doi:10.1016/0021-9150(85)90177-7.

    PubMed  CAS  Google Scholar 

  40. Forster, C., Kietz, S., Hultenby, K., Warner, M., & Gustafsson, J. A. (2004). Characterization of the ERbeta−/−mouse heart. Proceedings of the National Academy of Sciences of the United States of America, 101, 14234–14239. doi:10.1073/pnas.0405571101.

    PubMed  Google Scholar 

  41. Garcia-Moll, X., Zouridakis, E., Cole, D., & Kaski, J. C. (2000). C-reactive protein in patients with chronic stable angina: Differences in baseline serum concentration between women and men. European Heart Journal, 21, 1598–1606. doi:10.1053/euhj.2000.2128.

    PubMed  CAS  Google Scholar 

  42. Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers, J., Paul-Clark, M. J., & Willoughby, D. A. (1999). Inducible cyclooxygenase may have anti-inflammatory properties. Nature Medicine, 5, 698–701. doi:10.1038/9550.

    PubMed  CAS  Google Scholar 

  43. Godsland, I. F., Crook, D., Worthington, M., Proudler, A. J., Felton, C., Sidhu, M., et al. (1993). Effects of a low-estrogen, desogestrel-containing oral contraceptive on lipid and carbohydrate metabolism. Contraception, 48, 217–227.

    PubMed  CAS  Google Scholar 

  44. Grady, D., Gebretsadik, T., Kerlikowske, K., Ernster, V., & Petitti, D. (1995). Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstetrics and Gynecology, 85, 304–313. doi:10.1016/0029-7844(94)00383-O.

    PubMed  CAS  Google Scholar 

  45. Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., et al. (2002). Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). Journal of the American Medical Association, 288, 49–57. doi:10.1001/jama.288.1.49.

    PubMed  Google Scholar 

  46. Greene, G. L., Gilna, P., Waterfield, M., Baker, A., Hort, Y., & Shine, J. (1986). Sequence and expression of human estrogen receptor complementary DNA. Science, 231, 1150–1154. doi:10.1126/science.3753802.

    PubMed  CAS  Google Scholar 

  47. Grodstein, F., Manson, J. E., Colditz, G. A., Willett, W. C., Speizer, F. E., & Stampfer, M. J. (2000). A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Annals of Internal Medicine, 133, 933–941.

    PubMed  CAS  Google Scholar 

  48. Grodstein, F., Manson, J. E., & Stampfer, M. J. (2006). Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation. Journal of Women’s Health, 15, 35–44. doi:10.1089/jwh.2006.15.35.

    PubMed  Google Scholar 

  49. Hale, S. L., Birnbaum, Y., & Kloner, R. A. (1996). beta-Estradiol, but not alpha-estradiol, reduced myocardial necrosis in rabbits after ischemia and reperfusion. American Heart Journal, 132, 258–262. doi:10.1016/S0002-8703(96)90419-6.

    PubMed  CAS  Google Scholar 

  50. Hale, S. L., Birnbaum, Y., & Kloner, R. A. (1997). Estradiol, administered acutely, protects ischemic myocardium in both female and male rabbits. Journal of Cardiovascular Pharmacology and Therapeutics, 2, 47–52. doi:10.1177/107424849700200106.

    PubMed  CAS  Google Scholar 

  51. Harnish, D. C., Liu, X., Kenney, T., Winneker, R. C., Chadwick, C., Friedrichs, G. S., et al. (2006). The pathway-selective estrogen receptor ligand WAY-169916 displays differential activity in ischemia-reperfusion injury models. Journal of Cardiovascular Pharmacology, 47, 788–795. doi:10.1097/01.fjc.0000211793.60528.f7.

    PubMed  CAS  Google Scholar 

  52. Harnish, D. C., Scicchitano, M. S., Adelman, S. J., Lyttle, C. R., & Karathanasis, S. K. (2000). The role of CBP in estrogen receptor cross-talk with nuclear factor-kappaB in HepG2 cells. Endocrinology, 141, 3403–3411. doi:10.1210/en.141.9.3403.

    PubMed  CAS  Google Scholar 

  53. Harvey, H. A., Kimura, M., & Hajba, A. (2006). Toremifene: An evaluation of its safety profile. The Breast, 15, 142–157. doi:10.1016/j.breast.2005.09.007.

    PubMed  Google Scholar 

  54. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., et al. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. Journal of the American Medical Association, 280, 605–613. doi:10.1001/jama.280.7.605.

    PubMed  CAS  Google Scholar 

  55. Hulley, S. B., & Grady, D. (2004). The WHI estrogen-alone trial—do things look any better? Journal of the American Medical Association, 291, 1769–1771. doi:10.1001/jama.291.14.1769.

    PubMed  CAS  Google Scholar 

  56. Juni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004). Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet, 364, 2021–2029. doi:10.1016/S0140-6736(04)17514-4.

    PubMed  CAS  Google Scholar 

  57. Karas, R. H., Patterson, B. L., & Mendelsohn, M. E. (1994). Human vascular smooth muscle cells contain functional estrogen receptor. Circulation, 89, 1943–1950.

    PubMed  CAS  Google Scholar 

  58. Kauffman, R. F., Bean, J. S., Fahey, K. J., Cullinan, G. J., Cox, D. A., & Bensch, W. R. (2000). Raloxifene and estrogen inhibit neointimal thickening after balloon injury in the carotid artery of male and ovariectomized female rats. Journal of Cardiovascular Pharmacology, 36, 459–465. doi:10.1097/00005344-200010000-00007.

    PubMed  CAS  Google Scholar 

  59. Keith, J. C., Jr., Albert, L. M., Leathurby, Y., Follettie, M., Wang, L., Borges-Marcucci, L., et al. (2005). The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappaB transcriptional activity in models of rheumatoid arthritis. Arthritis Research & Therapy, 7, R427–R438. doi:10.1186/ar1692.

    CAS  Google Scholar 

  60. Kim, Y. D., Chen, B., Beauregard, J., Kouretas, P., Thomas, G., Farhat, M. Y., et al. (1996). 17 beta-Estradiol prevents dysfunction of canine coronary endothelium and myocardium and reperfusion arrhythmias after brief ischemia/reperfusion. Circulation, 94, 2901–2908.

    PubMed  CAS  Google Scholar 

  61. Kimelberg, H. K., Feustel, P. J., Jin, Y., Paquette, J., Boulos, A., Keller, R. W., Jr., et al. (2000). Acute treatment with tamoxifen reduces ischemic damage following middle cerebral artery occlusion. Neuroreport, 11, 2675–2679. doi:10.1097/00001756-200008210-00014.

    PubMed  CAS  Google Scholar 

  62. Kuiper, G. G., Carlsson, B., Grandien, K., Enmark, E., Haggblad, J., Nilsson, S., et al. (1997). Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology, 138, 863–870. doi:10.1210/en.138.3.863.

    PubMed  CAS  Google Scholar 

  63. Kuiper, G. G., & Gustafsson, J. A. (1997). The novel estrogen receptor-beta subtype: Potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Letters, 410, 87–90. doi:10.1016/S0014-5793(97)00413-4.

    PubMed  CAS  Google Scholar 

  64. Kusama, M., Miyauchi, K., Aoyama, H., Sano, M., Kimura, M., Mitsuyama, S., et al. (2004). Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. Breast Cancer Research and Treatment, 88, 1–8. doi:10.1007/s10549-004-4384-z.

    PubMed  CAS  Google Scholar 

  65. Lang, T. J. (2004). Estrogen as an immunomodulator. Clinical Immunology (Orlando, Fla.), 113, 224–230. doi:10.1016/j.clim.2004.05.011.

    CAS  Google Scholar 

  66. Levin, E. R. (1999). Cellular functions of the plasma membrane estrogen receptor. Trends in Endocrinology and Metabolism, 10, 374–377. doi:10.1016/S1043-2760(99)00192-7.

    PubMed  CAS  Google Scholar 

  67. Levine, R. L., Chen, S. J., Durand, J., Chen, Y. F., & Oparil, S. (1996). Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation, 94, 2221–2227.

    PubMed  CAS  Google Scholar 

  68. Li, L., Haynes, M. P., & Bender, J. R. (2003). Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 4807–4812. doi:10.1073/pnas.0831079100.

    PubMed  CAS  Google Scholar 

  69. Li, Y., & Kloner, R. A. (1995). Is there a gender difference in infarct size and arrhythmias following experimental coronary occlusion and reperfusion? Journal of Thrombosis and Thrombolysis, 2, 221–225.

    PubMed  Google Scholar 

  70. Losordo, D. W., Kearney, M., Kim, E. A., Jekanowski, J., & Isner, J. M. (1994). Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation, 89, 1501–1510.

    PubMed  CAS  Google Scholar 

  71. Lucchesi, B. R. (1990). Modulation of leukocyte-mediated myocardial reperfusion injury. Annual Review of Physiology, 52, 561–576. doi:10.1146/annurev.ph.52.030190.003021.

    PubMed  CAS  Google Scholar 

  72. McCord, J. M. (1985). Oxygen-derived free radicals in postischemic tissue injury. The New England Journal of Medicine, 312, 159–163.

    PubMed  CAS  Google Scholar 

  73. Meldrum, D. R. (1998). Tumor necrosis factor in the heart. The American Journal of Physiology, 274, R577–R595.

    PubMed  CAS  Google Scholar 

  74. Mendelsohn, M. E., & Karas, R. H. (1999). The protective effects of estrogen on the cardiovascular system. The New England Journal of Medicine, 340, 1801–1811. doi:10.1056/NEJM199906103402306.

    PubMed  CAS  Google Scholar 

  75. Mosca, L., Collins, P., Herrington, D. M., Mendelsohn, M. E., Pasternak, R. C., Robertson, R. M., et al. (2001). Hormone replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation, 104, 499–503. doi:10.1161/hc2901.092200.

    PubMed  CAS  Google Scholar 

  76. Nabulsi, A. A., Folsom, A. R., White, A., Patsch, W., Heiss, G., Wu, K. K., et al. (1993). Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The atherosclerosis risk in communities study investigators. The New England Journal of Medicine, 328, 1069–1075. doi:10.1056/NEJM199304153281501.

    PubMed  CAS  Google Scholar 

  77. Nakagomi, A., Freedman, S. B., & Geczy, C. L. (2000). Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: Relationship with age, sex, and hormone replacement treatment. Circulation, 101, 1785–1791.

    PubMed  CAS  Google Scholar 

  78. Nijmeijer, R., Lagrand, W. K., Lubbers, Y. T., Visser, C. A., Meijer, C. J., Niessen, H. W., et al. (2003). C-reactive protein activates complement in infarcted human myocardium. American Journal of Pathology, 163, 269–275.

    PubMed  CAS  Google Scholar 

  79. Nuedling, S., Karas, R. H., Mendelsohn, M. E., Katzenellenbogen, J. A., Katzenellenbogen, B. S., Meyer, R., et al. (2001). Activation of estrogen receptor beta is a prerequisite for estrogen-dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes. FEBS Letters, 502, 103–108. doi:10.1016/S0014-5793(01)02675-8.

    PubMed  CAS  Google Scholar 

  80. Osborne, C. K. (1998). Tamoxifen in the treatment of breast cancer. The New England Journal of Medicine, 339, 1609–1618. doi:10.1056/NEJM199811263392207.

    PubMed  CAS  Google Scholar 

  81. Pappas, T. C., Gametchu, B., & Watson, C. S. (1995). Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. The FASEB Journal, 9, 404–410.

    PubMed  CAS  Google Scholar 

  82. Park, J. L., & Lucchesi, B. R. (1999). Mechanisms of myocardial reperfusion injury. The Annals of Thoracic Surgery, 68, 1905–1912. doi:10.1016/S0003-4975(99)01073-5.

    PubMed  CAS  Google Scholar 

  83. Patten, R. D., Pourati, I., Aronovitz, M. J., Baur, J., Celestin, F., Chen, X., et al. (2004). 17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circulation Research, 95, 692–699. doi:10.1161/01.RES.0000144126.57786.89.

    PubMed  CAS  Google Scholar 

  84. Pelzer, T., Loza, P. A., Hu, K., Bayer, B., Dienesch, C., Calvillo, L., et al. (2005). Increased mortality and aggravation of heart failure in estrogen receptor-beta knockout mice after myocardial infarction. Circulation, 111, 1492–1498. doi:10.1161/01.CIR.0000159262.18512.46.

    PubMed  CAS  Google Scholar 

  85. Pettersson, K., & Gustafsson, J. A. (2001). Role of estrogen receptor beta in estrogen action. Annual Review of Physiology, 63, 165–192. doi:10.1146/annurev.physiol.63.1.165.

    PubMed  CAS  Google Scholar 

  86. Rau, S. W., Dubal, D. B., Bottner, M., Gerhold, L. M., & Wise, P. M. (2003). Estradiol attenuates programmed cell death after stroke-like injury. The Journal of Neuroscience, 23, 11420–11426.

    PubMed  CAS  Google Scholar 

  87. Ray, A., Prefontaine, K. E., & Ray, P. (1994). Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. The Journal of Biological Chemistry, 269, 12940–12946.

    PubMed  CAS  Google Scholar 

  88. Ray, P., Ghosh, S. K., Zhang, D. H., & Ray, A. (1997). Repression of interleukin-6 gene expression by 17 beta-estradiol: Inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Letters, 409, 79–85. doi:10.1016/S0014-5793(97)00487-0.

    PubMed  CAS  Google Scholar 

  89. Razandi, M., Pedram, A., Greene, G. L., & Levin, E. R. (1999). Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: Studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Molecular Endocrinology (Baltimore, Md.), 13, 307–319. doi:10.1210/me.13.2.307.

    CAS  Google Scholar 

  90. Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B., & Prossnitz, E. R. (2005). A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science, 307, 1625–1630. doi:10.1126/science.1106943.

    PubMed  CAS  Google Scholar 

  91. Riggs, B. L., & Hartmann, L. C. (2003). Selective estrogen-receptor modulators—Mechanisms of action and application to clinical practice. The New England Journal of Medicine, 348, 618–629. doi:10.1056/NEJMra022219.

    PubMed  CAS  Google Scholar 

  92. Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women’s Health Initiative randomized controlled trial. Journal of the American Medical Association, 288, 321–333. doi:10.1001/jama.288.3.321.

    PubMed  CAS  Google Scholar 

  93. Sbarouni, E., Iliodromitis, E. K., Bofilis, E., Kyriakides, Z. S., & Kremastinos, D. T. (2003). Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size. European Journal of Pharmacology, 467, 163–168. doi:10.1016/S0014-2999(03)01627-3.

    PubMed  CAS  Google Scholar 

  94. Schuit, S. C., de Jong, F. H., Stolk, L., Koek, W. N., van Meurs, J. B., Schoofs, M. W., et al. (2005). Estrogen receptor alpha gene polymorphisms are associated with estradiol levels in postmenopausal women. European Journal of Endocrinology, 153, 327–334. doi:10.1530/eje.1.01973.

    PubMed  CAS  Google Scholar 

  95. Shaw, L., Taggart, M. J., & Austin, C. (2000). Mechanisms of 17 beta-oestradiol induced vasodilatation in isolated pressurized rat small arteries. British Journal of Pharmacology, 129, 555–565. doi:10.1038/sj.bjp.0703084.

    PubMed  CAS  Google Scholar 

  96. Silvestri, A., Gebara, O., Vitale, C., Wajngarten, M., Leonardo, F., Ramires, J. A., et al. (2003). Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation, 107, 3165–3169. doi:10.1161/01.CIR.0000074208.02226.5E.

    PubMed  CAS  Google Scholar 

  97. Siris, E. S., Harris, S. T., Eastell, R., Zanchetta, J. R., Goemaere, S., Diez-Perez, A., et al. (2005). Skeletal effects of raloxifene after 8 years: Results from the continuing outcomes relevant to Evista (CORE) study. Journal of Bone and Mineral Research, 20, 1514–1524. doi:10.1359/JBMR.050509.

    PubMed  CAS  Google Scholar 

  98. Skavdahl, M., Steenbergen, C., Clark, J., Myers, P., Demianenko, T., Mao, L., et al. (2005). Estrogen receptor-beta mediates male–female differences in the development of pressure overload hypertrophy. American Journal of Physiology. Heart and Circulatory Physiology, 288, H469–H476. doi:10.1152/ajpheart.00723.2004.

    PubMed  CAS  Google Scholar 

  99. Speir, E., Yu, Z. X., Takeda, K., Ferrans, V. J., & Cannon, R. O., III. (2000). Competition for p300 regulates transcription by estrogen receptors and nuclear factor-kappaB in human coronary smooth muscle cells. Circulation Research, 87, 1006–1011.

    PubMed  CAS  Google Scholar 

  100. Squadrito, F., Altavilla, D., Squadrito, G., Campo, G. M., Arlotta, M., Arcoraci, V., et al. (1997). 17Beta-oestradiol reduces cardiac leukocyte accumulation in myocardial ischaemia reperfusion injury in rat. European Journal of Pharmacology, 335, 185–192. doi:10.1016/S0014-2999(97)01201-6.

    PubMed  CAS  Google Scholar 

  101. Stamatelopoulos, K. S., Lekakis, J. P., Poulakaki, N. A., Papamichael, C. M., Venetsanou, K., Aznaouridis, K., et al. (2004). Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. American Heart Journal, 147, 1093–1099. doi:10.1016/j.ahj.2003.12.029.

    PubMed  CAS  Google Scholar 

  102. Steenbergen, C., Murphy, E., Levy, L., & London, R. E. (1987). Elevation in cytosolic free calcium concentration early in myocardial ischemia in perfused rat heart. Circulation Research, 60, 700–707.

    PubMed  CAS  Google Scholar 

  103. Stein, B., & Yang, M. X. (1995). Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Molecular and Cellular Biology, 15, 4971–4979.

    PubMed  CAS  Google Scholar 

  104. Strong, J. P. (1999). Atherosclerosis in the young: Risk and prevention. Hospital Practice (Off Ed), 34, 15–16, 19.

    Google Scholar 

  105. Sun, J., Picht, E., Ginsburg, K. S., Bers, D. M., Steenbergen, C., & Murphy, E. (2006). Hypercontractile female hearts exhibit increased S-nitrosylation of the L-type Ca2+ channel alpha1 subunit and reduced ischemia/reperfusion injury. Circulation Research, 98, 403–411. doi:10.1161/01.RES.0000202707.79018.0a.

    PubMed  CAS  Google Scholar 

  106. Sun, W. H., Keller, E. T., Stebler, B. S., & Ershler, W. B. (1998). Estrogen inhibits phorbol ester-induced I kappa B alpha transcription and protein degradation. Biochemical and Biophysical Research Communications, 244, 691–695. doi:10.1006/bbrc.1998.8324.

    PubMed  CAS  Google Scholar 

  107. Tanhehco, E. J., Lee, H., & Lucchesi, B. R. (2000). Sublytic complement attack reduces infarct size in rabbit isolated hearts: Evidence for C5a-mediated cardioprotection. Immunopharmacology, 49, 391–399. doi:10.1016/S0162-3109(00)00258-7.

    PubMed  CAS  Google Scholar 

  108. Tanhehco, E. J., Yasojima, K., McGeer, P. L., Washington, R. A., Kilgore, K. S., Homeister, J. W., et al. (1999). Preconditioning reduces tissue complement gene expression in the rabbit isolated heart. The American Journal of Physiology, 277, H2373–H2380.

    PubMed  CAS  Google Scholar 

  109. Thurberg, B. L., & Collins, T. (1998). The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Current Opinion in Lipidology, 9, 387–396. doi:10.1097/00041433-199810000-00002.

    PubMed  CAS  Google Scholar 

  110. Toran-Allerand, C. D. (2004). Minireview: A plethora of estrogen receptors in the brain: Where will it end? Endocrinology, 145, 1069–1074. doi:10.1210/en.2003-1462.

    PubMed  CAS  Google Scholar 

  111. Torzewski, M., Torzewski, J., Bowyer, D. E., Waltenberger, J., Fitzsimmons, C., Hombach, V., et al. (1997). Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions. Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 2448–2452.

    PubMed  CAS  Google Scholar 

  112. trial WGftP. (1995). Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI). Trial the writing group for the PEPI Trial. Journal of the American Medical Association, 273, 199–208. doi:10.1001/jama.273.3.199.

    Google Scholar 

  113. Tsai, C. H., Su, S. F., Chou, T. F., & Lee, T. M. (2002). Differential effects of sarcolemmal and mitochondrial K(ATP) channels activated by 17 beta-estradiol on reperfusion arrhythmias and infarct sizes in canine hearts. The Journal of Pharmacology and Experimental Therapeutics, 301, 234–240. doi:10.1124/jpet.301.1.234.

    PubMed  CAS  Google Scholar 

  114. Vane, J. (1994). Towards a better aspirin. Nature, 367, 215–216. doi:10.1038/367215a0.

    PubMed  CAS  Google Scholar 

  115. Wagner, J. D., Clarkson, T. B., St Clair, R. W., Schwenke, D. C., Shively, C. A., & Adams, M. R. (1991). Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. The Journal of Clinical Investigation, 88, 1995–2002. doi:10.1172/JCI115526.

    PubMed  CAS  Google Scholar 

  116. Walsh, B. W., Schiff, I., Rosner, B., Greenberg, L., Ravnikar, V., & Sacks, F. M. (1991). Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. The New England Journal of Medicine, 325, 1196–1204.

    PubMed  CAS  Google Scholar 

  117. Williams, J. K., Adams, M. R., Herrington, D. M., & Clarkson, T. B. (1992). Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. Journal of the American College of Cardiology, 20, 452–457.

    Article  PubMed  CAS  Google Scholar 

  118. Williams, J. K., Anthony, M. S., Honore, E. K., Herrington, D. M., Morgan, T. M., Register, T. C., et al. (1995). Regression of atherosclerosis in female monkeys. Arteriosclerosis, Thrombosis, and Vascular Biology, 15, 827–836.

    PubMed  CAS  Google Scholar 

  119. Williams, J. K., Wagner, J. D., Li, Z., Golden, D. L., & Adams, M. R. (1997). Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 403–408.

    PubMed  CAS  Google Scholar 

  120. Writing, G. (1995). Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The writing group for the PEPI Trial. Journal of the American Medical Association, 273, 199–208. doi:10.1001/jama.273.3.199.

    Google Scholar 

  121. Writing, G. (1998). Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet, 351, 1451–1467. doi:10.1016/S0140-6736(97)11423-4.

    Google Scholar 

  122. Wyckoff, M. H., Chambliss, K. L., Mineo, C., Yuhanna, I. S., Mendelsohn, M. E., Mumby, S. M., et al. (2001). Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Galpha(i). The Journal of Biological Chemistry, 276, 27071–27076. doi:10.1074/jbc.M100312200.

    PubMed  CAS  Google Scholar 

  123. Zhai, P., Eurell, T. E., Cooke, P. S., Lubahn, D. B., & Gross, D. R. (2000). Myocardial ischemia-reperfusion injury in estrogen receptor-alpha knockout and wild-type mice. American Journal of Physiology. Heart and Circulatory Physiology, 278, H1640–H1647.

    PubMed  CAS  Google Scholar 

  124. Zhao, X., Macbride, M. M., Peterson, B. R., Pfaff, D. W., & Vasudevan, N. (2005). Calcium flux in neuroblastoma cells is a coupling mechanism between non-genomic and genomic modes of estrogens. Neuroendocrinology, 81, 174–182. doi:10.1159/000087000.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, University of Michigan Medical School, 1301C Medical Science Research Building III, Ann Arbor, MI, 48109-5632, USA

    Erin A. Booth & Benedict R. Lucchesi

Authors
  1. Erin A. Booth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benedict R. Lucchesi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erin A. Booth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Booth, E.A., Lucchesi, B.R. Estrogen-Mediated Protection in Myocardial Ischemia-Reperfusion Injury. Cardiovasc Toxicol 8, 101–113 (2008). https://doi.org/10.1007/s12012-008-9022-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12012-008-9022-2

Keywords

Search

Navigation